Agreed and common mis-perception. BP does not start with

Agreed and common mis-perception. BP does not start with pps in any buyout scenario. It centers on the cold hard math of addressable market based on clinical data, percent projected market share, timeline and costs to approval, patent protection timeline etc and should rightfully respect the plethora of indications for which we have clinical data with which our current pps has paid for with dilution, patience and risk. A figure is arrived at for an offer. PPS is what that offer translates given the shares outstanding at the time. BP does not say “hey” “we see your 24 cents a share and we’ll triple it.” Value is driven by the drug, NOT pps!